ATE485056T1 - Verbesserte impfstoffe - Google Patents

Verbesserte impfstoffe

Info

Publication number: ATE485056T1
Authority: AT; Austria
Prior art keywords: improved vaccines; pathogens; xzxz; xzx; immunostimulatory
Prior art date: 2003-03-24

Application number

AT04722281T

Other languages

English (en)

Inventor

Michael Buschle

Andre Habel

Joerg Fritz

Karin Prinz

Karen Lingnau

Original Assignee

Intercell Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-24

Filing date

2004-03-22

Publication date

2010-11-15

2004-03-22 Application filed by Intercell Ag filed Critical Intercell Ag

2010-11-15 Application granted granted Critical

2010-11-15 Publication of ATE485056T1 publication Critical patent/ATE485056T1/de

Links

229960005486 vaccine Drugs 0.000 title abstract 2
VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 abstract 1
MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
150000007513 acids Chemical class 0.000 abstract 1
239000000427 antigen Substances 0.000 abstract 1
102000036639 antigens Human genes 0.000 abstract 1
108091007433 antigens Proteins 0.000 abstract 1
VGONTNSXDCQUGY-UHFFFAOYSA-N desoxyinosine Natural products C1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 VGONTNSXDCQUGY-UHFFFAOYSA-N 0.000 abstract 1
230000003308 immunostimulating effect Effects 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
244000052769 pathogen Species 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
244000052613 viral pathogen Species 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Communicable Diseases (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Biochemistry (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT04722281T 2003-03-24 2004-03-22 Verbesserte impfstoffe ATE485056T1 (de)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP03450072		2003-03-24
EP03450084		2003-04-11
EP03450171		2003-07-11
PCT/EP2004/003002 WO2004084938A1 (en)	2003-03-24	2004-03-22	Improved vaccines

Publications (1)

Publication Number	Publication Date
ATE485056T1 true ATE485056T1 (de)	2010-11-15

Family

ID=33101777

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04722281T ATE485056T1 (de)	2003-03-24	2004-03-22	Verbesserte impfstoffe

Country Status (9)

Country	Link
US (3)	US7704514B2 (de)
EP (2)	EP2345420B1 (de)
JP (3)	JP4676426B2 (de)
AT (1)	ATE485056T1 (de)
AU (2)	AU2004224746B2 (de)
CA (1)	CA2517673C (de)
DE (1)	DE602004029657D1 (de)
ES (1)	ES2562456T3 (de)
WO (1)	WO2004084938A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001093905A1 (en)	2000-06-08	2001-12-13	Intercell Biomedizinische Forschungs- Und Entwicklungs Ag	Immunostimulatory oligodeoxynucleotides
AT410635B (de) *	2000-10-18	2003-06-25	Cistem Biotechnologies Gmbh	Vakzin-zusammensetzung
DE10144906B4 (de)	2001-09-12	2013-11-28	Novartis Vaccines And Diagnostics Gmbh	Verfahren zur großtechnischen Herstellung von Impfstoffen
CA2452909A1 (en) *	2001-12-07	2003-06-13	Intercell Ag	Immunostimulatory oligodeoxynucleotides
ES2562456T3 (es) *	2003-03-24	2016-03-04	Valneva Austria Gmbh	Uso de un adyuvante que induce una respuesta inmune Th1 para mejorar las respuestas inmunes
CA2530062A1 (en) *	2003-07-11	2005-01-20	Intercell Ag	Hcv vaccines
CA2583026A1 (en) *	2004-10-29	2006-05-04	Intercell Ag	Hcv vaccines for chronic hcv patients
EP1787660A1 (de) *	2005-11-22	2007-05-23	GBF Gesellschaft für Biotechnologische Forschung mbH	Neue Adjuvanten auf der Basis von Bisacyloxypropylcystein-Konjugaten und ihre Verwendungen in pharmazeuthischen Zusammensetzungen.
PL2121011T3 (pl) *	2006-12-06	2014-10-31	Novartis Ag	Szczepionki zawierające antygeny czterech szczepów wirusa grypy
WO2009024534A2 (en) *	2007-08-17	2009-02-26	Intercell Ag	Japanese encephalitis virus (jev) and tick-borne encephalitis virus (tbev) peptides stimulating human t cell responses
US20100015171A1 (en)	2008-07-15	2010-01-21	Statens Serum Institute	Vaccines comprising tb 10.4
EP2313116A1 (de) *	2008-08-08	2011-04-27	Intercell AG	Verbesserte bakterielle polysaccharid-polypeptid-konjugat-zusammensetzungen
NZ591768A (en)	2008-09-18	2012-11-30	Novartis Ag	Vaccine adjuvant combinations
AU2010212550B2 (en)	2009-02-10	2016-03-10	Seqirus UK Limited	Influenza vaccines with reduced amounts of squalene
US8858958B2 (en) *	2009-08-27	2014-10-14	Novartis Ag	Adjuvant comprising aluminum, oligonucleotide and polycation
WO2011030218A1 (en)	2009-09-10	2011-03-17	Novartis Ag	Combination vaccines against respiratory tract diseases
GB0917003D0 (en)	2009-09-28	2009-11-11	Novartis Vaccines Inst For Global Health Srl	Purification of bacterial vesicles
GB0917002D0 (en)	2009-09-28	2009-11-11	Novartis Vaccines Inst For Global Health Srl	Improved shigella blebs
US20130022639A1 (en)	2009-09-30	2013-01-24	Novartis Ag	Expression of meningococcal fhbp polypeptides
WO2011101465A1 (en)	2010-02-19	2011-08-25	Intercell Ag	Ic31 nanoparticles
WO2012020326A1 (en)	2010-03-18	2012-02-16	Novartis Ag	Adjuvanted vaccines for serogroup b meningococcus
CA2803239A1 (en)	2010-06-25	2011-12-29	Novartis Ag	Combinations of meningococcal factor h binding proteins
RU2451373C1 (ru) *	2010-09-10	2012-05-20	Открытое Акционерное Общество "Уральское проектно-конструкторское бюро "Деталь"	Активная фазированная антенная решетка
GB201017519D0 (en)	2010-10-15	2010-12-01	Novartis Vaccines Inst For Global Health S R L	Vaccines
EP2755683B1 (de)	2011-09-14	2019-04-03	GlaxoSmithKline Biologicals SA	Verfahren zur herstellung von saccharidprotein-glykokonjugaten
WO2014044690A1 (en)	2012-09-18	2014-03-27	Valneva Austria Gmbh	Improved vaccines
RU2662970C2 (ru)	2012-09-18	2018-07-31	Новартис Аг	Везикулы наружной мембраны
US20150220643A1 (en) *	2014-01-31	2015-08-06	International Business Machines Corporation	Scoring properties of social media postings
US10816554B2 (en)	2014-04-04	2020-10-27	The Board Of Trustees Of The Leland Stanford Junior University	Ligand discovery for T cell receptors
EP4357355A3 (de)	2015-12-23	2024-09-25	Valneva SE	Virusreinigung
AU2017332854B2 (en)	2016-09-21	2024-11-14	The Governors Of The University Of Alberta	Hepatitis C virus immunogenic compositions and methods of use thereof
AU2017345766A1 (en) *	2016-10-21	2019-05-16	Modernatx, Inc.	Human cytomegalovirus vaccine
CN108314708B (zh) *	2017-01-17	2021-03-05	南京农业大学	一种具有促进疫苗免疫反应的法氏囊活性九肽及其应用
PH12021552736A1 (en)	2019-05-20	2022-07-11	Valneva Se	A subunit vaccine for treatment or prevention of a respiratory tract infection
CN115120713A (zh) *	2021-03-25	2022-09-30	四川大学	氢氧化铝-CpG寡核苷酸-多肽复合佐剂、疫苗及制备方法和用途
US20240358812A1 (en)	2021-04-09	2024-10-31	Valneva Se	Human metapneumovirus combination vaccine

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5683864A (en)	1987-11-18	1997-11-04	Chiron Corporation	Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
EP0468520A3 (en)	1990-07-27	1992-07-01	Mitsui Toatsu Chemicals, Inc.	Immunostimulatory remedies containing palindromic dna sequences
EP1227323B2 (de)	1990-08-25	2011-01-19	Bioprocess Pty Ltd	Nicht-A, nicht-B Hepatitis Virus Antigen, und diagnostische Verfahren.
KR0185426B1 (ko)	1991-06-24	1999-04-01	로버트 피. 블랙버언	씨형 간염 바이러스 폴리펩티드
US6419931B1 (en)	1991-08-26	2002-07-16	Epimmune Inc.	Compositions and methods for eliciting CTL immunity
US6037135A (en)	1992-08-07	2000-03-14	Epimmune Inc.	Methods for making HLA binding peptides and their uses
US5333965A (en)	1992-01-31	1994-08-02	Mailey John W	In situ modular fastening system
JP3908271B2 (ja)	1993-03-05	2007-04-25	エピミューン，インコーポレイティド	Ｈｌａ−ａ２．１結合ペプチドおよびそれらの使用
ATE551423T1 (de)	1993-04-27	2012-04-15	Innogenetics Nv	Sequenzen von hepatitis c virus-genotypen sowie ihre verwendungen als therapeutika und diagnostika
US5709995A (en)	1994-03-17	1998-01-20	The Scripps Research Institute	Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
WO1995026204A1 (en)	1994-03-25	1995-10-05	Isis Pharmaceuticals, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
JPH10503473A (ja)	1994-04-08	1998-03-31	アメリカ合衆国	細胞傷害性ｔリンパ球刺激およびｈｃｖ曝露診断用ｃ型肝炎ウイルスコアペプチド
AU2287595A (en)	1994-04-11	1995-10-30	Ixsys, Inc.	Class i peptide binding motifs
WO1996002555A1 (en)	1994-07-15	1996-02-01	The University Of Iowa Research Foundation	Immunomodulatory oligonucleotides
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
GB9620795D0 (en)	1996-10-05	1996-11-20	Smithkline Beecham Plc	Vaccines
CO4600681A1 (es)	1996-02-24	1998-05-08	Boehringer Ingelheim Pharma	Composicion farmaceutica para la modulacion inmunitaria
JP4111403B2 (ja)	1996-10-11	2008-07-02	ザリージェンツオブザユニバーシティーオブカリフォルニア	免疫刺激ポリヌクレオチド／免疫調節分子複合体
US6562345B1 (en)	1996-11-12	2003-05-13	City Of Hope	Immuno-reactive peptide CTL epitopes of human cytomegalovirus
US6413517B1 (en)	1997-01-23	2002-07-02	Epimmune, Inc.	Identification of broadly reactive DR restricted epitopes
WO1998037919A1 (en)	1997-02-28	1998-09-03	University Of Iowa Research Foundation	USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
AU753688B2 (en)	1997-03-10	2002-10-24	Ottawa Civic Loeb Research Institute	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
JP2001526688A (ja)	1997-05-19	2001-12-18	メルクエンドカンパニーインコーポレーテッド	オリゴヌクレオチドアジュバント
AU7690898A (en)	1997-05-20	1998-12-11	Ottawa Civic Hospital Loeb Research Institute	Vectors and methods for immunization or therapeutic protocols
DE69809581T2 (de)	1997-09-19	2003-08-14	Valtion Teknillinen Tutkimuskeskus, Espoo	Gasfilter
GB9727262D0 (en) *	1997-12-24	1998-02-25	Smithkline Beecham Biolog	Vaccine
DE19803453A1 (de)	1998-01-30	1999-08-12	Boehringer Ingelheim Int	Vakzine
US6218371B1 (en)	1998-04-03	2001-04-17	University Of Iowa Research Foundation	Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
CA2328602A1 (en)	1998-05-06	1999-11-11	University Of Iowa Research Foundation	Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
ES2281179T3 (es)	1998-06-09	2007-09-16	Andrea D. Branch	Nuevos peptidos del virus de la hepatitis c y usos de los mismos.
WO2000011186A1 (en)	1998-08-21	2000-03-02	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Modified hcv peptide vaccines
AU750587B2 (en)	1998-10-16	2002-07-25	Smithkline Beecham Biologicals (Sa)	Adjuvant systems and vaccines
WO2000031542A1 (en)	1998-11-24	2000-06-02	Thomas Jefferson University	Detection of t cell stimulating tumor antigens
AU3215800A (en)	1999-01-27	2000-08-18	Epimmune, Inc.	Identification of broadly reactive hla restricted t cell epitopes
CN1227030C (zh) *	1999-04-19	2005-11-16	史密丝克莱恩比彻姆生物有限公司	包含皂甙和免疫刺激寡核苷酸的佐剂组合物
WO2001021189A1 (en)	1999-07-19	2001-03-29	Epimmune Inc.	Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
GB9921146D0 (en) *	1999-09-07	1999-11-10	Smithkline Beecham Biolog	Novel composition
AT408721B (de)	1999-10-01	2002-02-25	Cistem Biotechnologies Gmbh	Pharmazeutische zusammensetzung enthaltend ein antigen
AT409085B (de) *	2000-01-28	2002-05-27	Cistem Biotechnologies Gmbh	Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
OA12168A (en)	2000-01-31	2006-05-08	Smithkline Beecham Biolog	Vaccine for the prophylactic or therapeutic immunization against HIV.
ATE375169T1 (de)	2000-04-14	2007-10-15	Intercell Ag	Modifizierte peptide enthaltende pharmazeutische präparationen
WO2001093905A1 (en) *	2000-06-08	2001-12-13	Intercell Biomedizinische Forschungs- Und Entwicklungs Ag	Immunostimulatory oligodeoxynucleotides
AT410173B (de) *	2000-06-08	2003-02-25	Cistem Biotechnologies Gmbh	Antigene zusammensetzung
AU2001289813B2 (en)	2000-08-17	2005-07-28	Intercell Ag	A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
WO2002026212A2 (en) *	2000-09-28	2002-04-04	Chiron Corporation	Microparticle compositions and methods for the manufacture thereof
US20020068274A1 (en)	2000-10-17	2002-06-06	Eisenlohr Laurence C.	Novel method for assessing recoding in vitro and in vivo
AT410635B (de)	2000-10-18	2003-06-25	Cistem Biotechnologies Gmbh	Vakzin-zusammensetzung
WO2002053184A2 (en) *	2001-01-05	2002-07-11	Intercell Ag	Uses for polycationic compounds as vaccine adjuvants
WO2002053185A2 (en) *	2001-01-05	2002-07-11	Intercell Ag	Anti-inflammatory use of polycationic compounds
CA2448031A1 (en)	2001-05-21	2002-11-28	Intercell Ag	Method for stabilising of nucleic acids
CA2452909A1 (en) *	2001-12-07	2003-06-13	Intercell Ag	Immunostimulatory oligodeoxynucleotides
CN1659436A (zh)	2002-02-28	2005-08-24	英特塞尔股份公司	分离配体的方法
FR2843115B1 (fr)	2002-08-02	2007-11-09	Commissariat Energie Atomique	Melange de peptides issus des proteines c et ns3 du virus de l'hepatite c et leurs applications
WO2004024182A2 (en)	2002-09-13	2004-03-25	Intercell Ag	Method for isolating hepatitis c virus peptides
ES2562456T3 (es) *	2003-03-24	2016-03-04	Valneva Austria Gmbh	Uso de un adyuvante que induce una respuesta inmune Th1 para mejorar las respuestas inmunes

2004
- 2004-03-22 ES ES10173930.8T patent/ES2562456T3/es not_active Expired - Lifetime
- 2004-03-22 CA CA2517673A patent/CA2517673C/en not_active Expired - Lifetime
- 2004-03-22 US US10/550,754 patent/US7704514B2/en not_active Expired - Lifetime
- 2004-03-22 AU AU2004224746A patent/AU2004224746B2/en not_active Expired
- 2004-03-22 EP EP10173930.8A patent/EP2345420B1/de not_active Expired - Lifetime
- 2004-03-22 AT AT04722281T patent/ATE485056T1/de active
- 2004-03-22 DE DE602004029657T patent/DE602004029657D1/de not_active Expired - Lifetime
- 2004-03-22 WO PCT/EP2004/003002 patent/WO2004084938A1/en not_active Ceased
- 2004-03-22 EP EP04722281A patent/EP1608402B1/de not_active Expired - Lifetime
- 2004-03-22 JP JP2006504798A patent/JP4676426B2/ja not_active Expired - Lifetime
2009
- 2009-06-17 AU AU2009202420A patent/AU2009202420B2/en not_active Expired
2010
- 2010-04-13 US US12/759,318 patent/US8784837B2/en not_active Expired - Lifetime
- 2010-10-22 JP JP2010237719A patent/JP2011042678A/ja not_active Withdrawn
2013
- 2013-01-30 JP JP2013015860A patent/JP5586717B2/ja not_active Expired - Lifetime
2014
- 2014-06-11 US US14/301,539 patent/US20150010595A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP4676426B2 (ja)	2011-04-27
JP5586717B2 (ja)	2014-09-10
JP2013121975A (ja)	2013-06-20
CA2517673C (en)	2013-08-13
JP2011042678A (ja)	2011-03-03
EP2345420B1 (de)	2016-01-06
WO2004084938A1 (en)	2004-10-07
CA2517673A1 (en)	2004-10-07
AU2009202420B2 (en)	2012-04-26
US7704514B2 (en)	2010-04-27
US20060263386A1 (en)	2006-11-23
AU2004224746A1 (en)	2004-10-07
AU2009202420A1 (en)	2009-07-09
EP1608402B1 (de)	2010-10-20
DE602004029657D1 (de)	2010-12-02
EP1608402A1 (de)	2005-12-28
US20100297170A1 (en)	2010-11-25
ES2562456T3 (es)	2016-03-04
EP2345420A1 (de)	2011-07-20
JP2006521320A (ja)	2006-09-21
US20150010595A1 (en)	2015-01-08
AU2004224746B2 (en)	2009-04-23
US8784837B2 (en)	2014-07-22

Legal Events

Date

Code

Title

Description

2011-04-15

UEP

Publication of translation of european patent specification

Ref document number: 1608402

Country of ref document: EP

Publication	Publication Date	Title
DE602004029657D1 (de)	2010-12-02	Verbesserte impfstoffe
WO2004030608A3 (en)	2005-03-10	Nanoemulsion vaccines
ATE451119T1 (de)	2009-12-15	Untereinheit-impfstoff gegen das respiratorische synzytialvirus
CY1112749T1 (el)	2016-02-10	Εμβολια διεγερσης/αναμνησης κατα της ελονοσιας
EP1594536A4 (de)	2006-09-06	Adjuvante influenza-vakzine
MXPA05009580A (es)	2005-10-19	Vacuna contra el virus de la influenza.
DE60226911D1 (de)	2008-07-10	Entwicklung einer Vakzine zur Prävention von Infektionen mit Filovirus bei Primaten
DE60012711D1 (de)	2004-09-09	Adjuvanszusammensetzungen zur erhöhung der immunantwort auf polynukleotid-basierende impfstoffe
DE60239594D1 (de)	2011-05-12	Influenza vakzinzusammensetzungen zur intradermaler verabreichung
WO2004060308A3 (en)	2006-10-05	Thiosemicarbazones as anti-virals and immunopotentiators
DE60121136D1 (de)	2006-08-10	Proteasom-influenzavirus-impfstoffzusammensetzung
CY1112879T1 (el)	2016-04-13	Συνθεση εμβολιου
WO2003080114A3 (en)	2003-11-06	Imidazoquinoline adjuvants for vaccines
CY1112014T1 (el)	2015-11-04	Συνθεσεις αντιβακτηριακων εμβολιων
CY1107457T1 (el)	2012-12-19	Εμβoλιο κατa του hpv
DE60012042D1 (de)	2004-08-12	Entepneumovirus und entsprechendes impfstoff
WO2007008918A3 (en)	2007-04-26	Virus vaccines comprising envelope-bound immunomodulatory proteins and methods of use thereof
DK1259259T3 (da)	2011-08-01	Mucosal adjuvansformulering
IL158428A0 (en)	2004-05-12	Vaccine composition comprising at least one hiv virus antigen
WO2005028496A3 (en)	2005-10-06	Vaccine for treatment and prevention of herpes simplex virus infection
AU2001292610A1 (en)	2002-03-22	Genetically engineered co-expression dna vaccines, construction methods and uses thereof
ATE521621T1 (de)	2011-09-15	Cpg-einzelstrang-desoxynukleotide zur verwendung als adjuvans
ATE375804T1 (de)	2007-11-15	Ribavirin-enthaltende vakzine
EP1471936A4 (de)	2006-10-25	Hiv-vakzine und anwendungsverfahren
MX2010006984A (es)	2010-10-25	Vacunas contra la malaria.